Ables Iannone Moore & Associates Inc. bought a new stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,353 shares of the biopharmaceutical company’s stock, valued at approximately $39,000.
Other large investors also recently made changes to their positions in the company. VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the period. GoalVest Advisory LLC increased its stake in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the last quarter. Creekmur Asset Management LLC purchased a new stake in shares of Pfizer during the fourth quarter worth $32,000. Tennessee Valley Asset Management Partners acquired a new stake in Pfizer during the fourth quarter valued at $36,000. Finally, DiNuzzo Private Wealth Inc. purchased a new position in Pfizer in the fourth quarter valued at about $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.
Pfizer Price Performance
Shares of NYSE PFE opened at $26.99 on Tuesday. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $39.87. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average of $27.57 and a two-hundred day moving average of $27.74.
Pfizer Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Shareholders of record on Friday, May 10th were issued a dividend of $0.42 per share. The ex-dividend date was Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.22%. Pfizer’s dividend payout ratio is currently -2,799.53%.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on PFE shares. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Morgan Stanley raised their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Monday. Ten analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $35.86.
Check Out Our Latest Stock Report on PFE
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
- Five stocks we like better than Pfizer
- What is the S&P 500 and How It is Distinct from Other Indexes
- 6 Reasons the S&P 500 Will Keep Rising This Year
- Following Congress Stock Trades
- CAVA’s Per-Restaurant Stock Value Outshines Chipotle’s
- How to Find Undervalued Stocks
- The Most Shorted Stocks in June: Hold, Short, or Squeeze?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.